Cullinan Therapeutics, Inc. (CGEM)
After hours:
- GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash and investments of $434.8 million as of March 31, 2024, plus gross proceeds of $280 million from April private placement extends cash runway into 2028 Company appoints David Meek to its Board of Directors CAMBRIDGE, Mass
- GuruFocus.com
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
Jennifer Michaelson, Chief Scientific Officer at Cullinan Therapeutics Inc (NASDAQ:CGEM), sold 63,606 shares of the company on May 7, 2024.
- GlobeNewswire
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. “I am pleased to welcome Mary Kay to Cullinan Therapeutics as Chief Financial Officer. This is a pivotal time for Cullinan as we expand into autoimmune diseases and continue to advance our clinical-stage oncology portfolio,” sa
